Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...

It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...

Troutman Pepper Locke senior associate Ryan Last explains when markets will start to significantly react to the upcoming pharma tariffs. In April of this year, President Trump announced plans to ...

In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, ...

In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...

Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...

They want to make sure we've got more control over that supply chain, so DARPA and the federal government are really ...

A July 17 response deadline requires documentation of trial-site governance in China, emphasizing due diligence, data protection controls, and monitoring of compliance at Xinjiang and PLA-affiliated ...

AbbVie entered into an agreement to acquire Apogee Therapeutics at a price of $135.11 for each outstanding. The deal is expected to be worth about $10.9 billion and will add Apogee’s entire pipeline ...

Pharmaceutical Executive: How will targeted onshoring impact pharma’s domestic manufacturing? Ryan Last: Targeted reshoring ...

For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...